Osaka-Based Fuso Pharma Voluntary Recalls Heparin Products
This article was originally published in PharmAsia News
Osaka-based Fuso Pharmaceutical announced May 2 it has started voluntarily recalling three kinds of heparin products in Japan, totaling 236,000 doses, due to a small amount of contaminant found in the products. According to the company, during a follow-up check after the products were distributed, the products were found to have the contaminant. The check found that the contaminant accounts for 0.2 percent, much less than 15-20 percent found in the U.S. cases. No adverse events related to Fuso's products were reported. A total of 1,237 Japanese dialysis facilities will be impacted by the recall. (Click here for more - Japanese language)
You may also be interested in...
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.
Stada has appointed a head of digital communications; PGEU elects new chair and vice-chair; and the new UK health claims committee unveils its first members.